Prosecution Insights
Last updated: November 16, 2026
Application No. 17/835,087

DEVICE AND METHOD FOR ELECTROTHERAPY AND/OR ELECTROPHYSIOLOGY

Non-Final OA §102§103
Filed
Jun 08, 2022
Priority
Jan 05, 2022 — IT 102022000000155
Examiner
ALTER MORSCHAUSER, ALYSSA MARGO
Art Unit
3792
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Wise Srl
OA Round
3 (Non-Final)
77%
Grant Probability
Favorable
3-4
OA Rounds
92%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allowance Rate
624 granted / 814 resolved
+6.7% vs TC avg
Strong +16% interview lift
Without
With
+15.6%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
35 currently pending
Career history
867
Total Applications
across all art units

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on February 9, 2026 has been entered. Response to Arguments Applicant’s arguments with respect to claims 1-7 and 15 have been considered but are moot because the amendments to the claims necessitated new ground of rejection, as presented below. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-5 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Lau et al. (US 2005/0102015 A1). As to claim 1, Lau et al. discloses a kit comprising a device for electrotherapy and/or electrophysiology and a delivery system for the device (Figures 27-28 and 33-34), wherein the device comprises: a lead (lead, depicted as 31 in Figures 32-36; [0011, 0101, 0145]); and a paddle (depicted in 15B; a paddle is comprised of paddle electrode, depicted as 32 in Figure 15B with at least one panel, depicted as 21 in Figure 15B; [0090]) comprising a paddle electrode (paddle electrode, depicted as 32 in Figure 15B) having an exposed surface configured to come into contact with living anatomy inside a patient's body (Figures 34-36); the paddle being reconfigurable between a transport configuration (Figure 28-29) and an operative configuration (Figures 34-36), a transverse extent of the paddle being smaller in the transport configuration than in the operative configuration ([0141]; “The cardiac harness 20, 60, 100 is collapsed to a low profile configuration and inserted into the distal end of the dilator tube shown in FIG. 28.”; Figures 28 and 33); and wherein the delivery system (delivery device, depicted as 140; Figures 33-34; [0141]) comprises: a flexible, hollow outer sheath (introducer tube, depicted as 142 in Figures 27 and 33-34; [0140-0141]) comprising a proximal end and a distal end the outer sheath being a tubular structure configured to bend to conform to patient anatomy while resisting buckling under compressive forces and being distinct from a percutaneous needle ([0140-0141]); and a hollow delivery sheath (dilator tube, depicted as 150 in Figures 28 and 33-34; [0141]) for receiving at least the paddle of the device in the transport configuration (Figures 28 and 33-34; [0141]), the delivery sheath being soft and flexible with low-friction properties enabling sliding and rotation within the outer sheath ([0141]; Figures 33-34); wherein the delivery sheath is configured to be inserted into the proximal end of the outer sheath and transported through the outer sheath to deliver the paddle of the device to the distal end of the outer sheath ([0141]). As to claim 2, Lau et al. discloses the delivery sheath comprises a proximal end and a distal end; the distal end comprising a distal opening, through which the paddle is capable of being received and ejected (Figure 27-28 and 32-34). As to claim 3, Lau et al. discloses the delivery sheath further comprises a proximal opening in the proximal end of the delivery sheath, through which the lead of the device is capable of passing (Figure 27-30 and 32-35). As to claim 4, Lau et al. discloses the paddle is configured to adopt its operative configuration automatically when ejected from the delivery sheath (Figure 33-35; [0145]). As to claim 5, Lau et al. discloses the device further comprises a stylet (ejection tube, depicted as 183 in Figures 37 and 42; [0150]) for controlling movement of the lead from outside the body (“the ejection tube has a distal end 184 and a proximal end 185, wherein the distal end of the ejection tube has a plate that fills the entire inner diameter of the ejection tube. The plate has a number of lumens 187 for receiving leads 31,132”and “After the cardiac harness is pushed over the epicardial surface of the heart, the ejection tube can be withdrawn proximally so that the tubing 157 and the leads 31,132 slide through lumens 189,188 respectively” [0150]; Therefore, since the ejection tube lumen retains the leads and facilitates placement during delivery, the ejection tube thus “controls movement of the lead outside the body” (i.e., during delivery; [0150]). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 6 and 15 are rejected under 35 U.S.C. 103 as being unpatentable over Lau et al. (US 2005/0102015 A1) in view of Hastings et al. (US 2004/0002643 A1). Lau et al. discloses the invention substantially as claimed with the paddle that is delivered at least partially within the delivery sheath and the delivery sheath is rotatable within the outer sheath to adjust the orientation of the paddle, but does not explicitly disclose “at least one fluoro-marker”. Navigation of medical devices in the presence of radiopaque materials with fluoroscopy is extremely well know procedure for implantation of medical devices. Hastings et al. discloses readiopaque marks that are visible under fluoroscopy during implantation ([0043]). It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the device of Lau et al. to include at least one fluoro-marker as disclosed by Hastings et al. in order to facilitate accurate delivery and proper orientation of the implantable medical device (Hstings et al.,[0001]) for optimized delivery and treatment for the patient. Claims 1-5 and 7 are rejected under 35 U.S.C. 103 as being unpatentable over Antonini et al. (US 2020/0316371 A1) in view of Lau et al. (US 2005/0102015 A1). As to claim 1, Antonini et al. discloses a kit ([0028]) comprising a device for electrotherapy and/or electrophysiology and a delivery system for the device ([0028]), wherein the device comprises: a lead (depicted as 2 in Figures 1-2, 5, 7 and 11; Abstract); and a paddle (depicted as 5 in Figure 1-2 and 10-11; Abstract) comprising a paddle electrode having an exposed surface configured to come into contact with living anatomy inside a patient's body (Abstract); the paddle being reconfigurable between a transport configuration and an operative configuration, a transverse extent of the paddle being smaller in the transport configuration than in the operative configuration (Abstract; [0145]; Figures 1 and 6); and wherein the delivery system comprises: a hollow delivery sheath (depicted as 49 in Figure 16; [0132]) for receiving at least the paddle of the device in the transport configuration (hollow body, depicted as 28; [0132]; Figures 1-2, 6 and 16), the delivery sheath being soft and flexible with low-friction properties enabling sliding and rotation ([138]). Antonini et al. additionally, discloses “(vi) therefore, a lower delivery sheath diameter over paddle width ratio is achieved in respect of known solutions; (vii) furthermore, the “omega”-like shape of the transport configuration of the paddle allows the folding of the paddle around a cylindrical lead, thus permitting the insertion in a catheter sheath that brings the paddle in the target position” ([0145]). Thus, Antonini et al. discloses a delivery sheath which retains the paddle as well as a catheter sheath for the delivery of the paddle to the target position. Thus, in accordance to the specification ([0145]), the examiner considers “the delivery sheath is configured to be inserted into the proximal end of the outer sheath (catheter sheath) and transported through the outer sheath to deliver the paddle of the device to the distal end of the outer sheath”. However, Antonini et al. does not explicitly disclose “the delivery sheath is configured to be inserted into the proximal end of the outer sheath and transported through the outer sheath to deliver the paddle of the device to the distal end of the outer sheath”. Lau et al. includes delivery of a medical device in a compressed or transport state in a delivery sheath (dilator tube, depicted as 150 in Figures 28 and 33-34; [0141]) that is disposed within an outer sheath (introducer tube, depicted as 142 in Figures 28 and 33-34; [0141]). It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the delivery system of Antonini et al. to include a flexible, hollow outer sheath transported the delivery sheath as disclosed by Lau et al. in order to provide the predictable results of delivering the medical device minimally invasively in a compressed state to the target position (Antonini et al, [0145]; Lau et al. Figure 33-36) in order to provide the predictable results of ensuring a low profile configuration and delivery (Lau et al. [0141, 0146]) to optimize delivery and minimize the invasiveness of the implantation surgery for improved patient treatment. Additionally, Antonini et al. discloses a percutaneous needle, depicted as 50 in Figure 16 which is different than the catheter, depicted as 49 in Figure 16. Therefore, the modified Antonini et al. discloses a hollow outer sheath distinct from a percutaneous needle. As to claim 2, the modified Antonini et al. discloses the delivery sheath comprises a proximal end and a distal end; the distal end comprising a distal opening, through which the paddle is capable of being received and ejected (Antonini et al., Figure 16 and Lau et al., Figures 29-30 and 33-34). As to claim 3, the modified Antonini et al. discloses the delivery sheath further comprises a proximal opening in the proximal end of the delivery sheath, through which the lead of the device is capable of passing (Antonini et al., Figure 16 and Lau et al., Figures 33-34). As to claim 4, the modified Antonini et al. discloses the paddle is configured to adopt its operative configuration automatically when ejected from the delivery sheath (Antonini et al., Figures 1-2 and Lau et al., Figures 33-34). As to claim 5, the modified Antonini et al. discloses the device further comprises a stylet for controlling movement of the lead from outside the body (Antonini et al., [0081, 0134, 0145]). As to claim 7, the modified Antonini et al. discloses the delivery system further comprises: a substantially rigid, hollow needle (percutaneous needle, depicted as 50 in Figures 7 and 16 of Antonini et al.) for creating a path into the body of the patient (Antonini et al., Figure 16); a guidewire (stylet, [0081, 0134, 0145]) capable of passing through the needle ( [0134]); since the stylet is received inside the lead which is passed through the percutaneous needle, Figures 7 and 16, the stylet is “capable of passing through the needle”. Additionally, the modified Antonini et al. discloses a hollow dilator (Lau et al., depicted as 150) capable of engagement around the guidewire and movement along the guidewire (since the dilator delivers the medical device, under the broadest reasonable interpretation the dilator is “capable of engagement around the guidewire and movement along the guidewire” since the guidewire (i.e., stylet) is disposed within the medical device (i.e. the lead)) with the hollow outer sheath is capable of engagement around the dilator to move with it along the guidewire. Claims 6 and 15 are rejected under 35 U.S.C. 103 as being unpatentable over the modified Antonini et al., as applied to claims 1-5 and 7 above, in further view of Hastings et al. (US 2004/0002643 A1). The modified Antonini et al. discloses the invention substantially as claimed with the paddle that is delivered at least partially within the delivery sheath and the delivery sheath is rotatable within the outer sheath to adjust the orientation of the paddle, but does not explicitly disclose “at least one fluoro-marker”. Navigation of medical devices in the presence of radiopaque materials with fluoroscopy is extremely well know procedure for implantation of medical devices. Hastings et al. discloses readiopaque marks that are visible under fluoroscopy during implantation ([0043]). It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the device of the modified Antonini et al. to include at least one fluoro-marker as disclosed by Hastings et al. in order to facilitate accurate delivery and proper orientation of the implantable medical device (Hstings et al.,[0001]) for optimized delivery and treatment for the patient. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ALYSSA M ALTER whose telephone number is (571)272-4939. The examiner can normally be reached M-F 8am-4pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, David E Hamaoui can be reached at (571) 270-5625. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ALYSSA M ALTER/Primary Examiner, Art Unit 3796
Read full office action

Prosecution Timeline

Jun 08, 2022
Application Filed
Jun 17, 2025
Non-Final Rejection mailed — §102, §103
Sep 22, 2025
Response Filed
Oct 08, 2025
Final Rejection mailed — §102, §103
Feb 09, 2026
Request for Continued Examination
Feb 28, 2026
Response after Non-Final Action
Oct 02, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773551
NEUROMODULATION TO ENHANCE PHYSICAL ACTIVITY BEHAVIOR
3y 5m to grant Granted Oct 27, 2026
Patent 12758771
Devices, Systems, And Methods For Applying Tumor-Treating Fields
3y 6m to grant Granted Oct 13, 2026
Patent 12746385
WRIST-WORN NERVE STIMULATOR AND USE METHOD THEREFOR
3y 3m to grant Granted Sep 29, 2026
Patent 12728264
DEVICE FOR STIMULATING HAIR GROWTH
3y 6m to grant Granted Sep 08, 2026
Patent 12714857
IMPEDANCE-MONITORING METHOD, ELECTRICAL-STIMULATION SYSTEM, AND COMPUTER-READABLE STORAGE MEDIUM
3y 9m to grant Granted Aug 25, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
77%
Grant Probability
92%
With Interview (+15.6%)
High
PTA Risk
Based on 814 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month